What a year 2024 has been for Trace Neuroscience, with one of the largest biopharma Series A rounds in recent years funding the development of a treatment for amyotrophic lateral sclerosis (ALS), which affects 5000 people in the UK.
UCLB played a crucial role in supporting the intellectual property behind the discovery and facilitating the collaboration between Trace Neuroscience and the academic team at
@ucl.
Find out more here: https://t.co/bAQSoCghvl